Table 1 Patient characteristics.
From: Single versus tandem autologous stem cell transplantation in newly diagnosed multiple myeloma
Feature | Characteristic | 1998–2007 (N = 3233) | 2008–2016 (N = 6610) | 2017–2021 (N = 2920) | p-value |
|---|---|---|---|---|---|
Sex (NA = 9) | Female | 1323 (40.9%) | 2563 (38.8%) | 1148 (39.4%) | p = 0.08 |
Male | 1910 (59.1%) | 4042 (61.2%) | 1768 (60.6%) | ||
t(4;14) (NA = 0) | yes | 9 (0.3%) | 269 (4.1%) | 342 (11.7%) | p < 0.001 |
no/not done | 3224 (99.7%) | 6341 (95.9%) | 2578 (88.3%) | ||
t(14;16) (NA = 0) | yes | 0 (0%) | 29 (0.4%) | 41 (1.4%) | p < 0.001 |
no/not done | 3233 (100%) | 6581 (99.6%) | 2879 (98.6%) | ||
del(17p) (NA = 0) | yes | 0 (0%) | 31 (0.5%) | 139 (4.8%) | p < 0.001 |
no/not done | 3233 (100%) | 6579 (99.5%) | 2781 (95.2%) | ||
ampl(1q) (NA = 0) | yes | 1 (0%) | 159 (2.4%) | 225 (7.7%) | p < 0.001 |
no/not done | 3232 (100%) | 6451 (97.6%) | 2695 (92.3%) | ||
ISS (NA = 8761) | I | 18 (41.9%) | 683 (39.4%) | 743 (33.4%) | p < 0.001 |
II | 14 (32.6%) | 531 (30.6%) | 811 (36.4%) | ||
III | 11 (25.6%) | 520 (30%) | 671 (30.2%) | ||
Karnofsky (NA = 2997) | 100 | 290 (27.9%) | 1535 (25.4%) | 780 (29.1%) | p < 0.001 |
90 | 487 (46.8%) | 3081 (51%) | 1225 (45.7%) | ||
80 | 190 (18.3%) | 1127 (18.6%) | 580 (21.6%) | ||
70 | 68 (6.5%) | 234 (3.9%) | 69 (2.6%) | ||
<=60 | 5 (0.5%) | 66 (1.1%) | 29 (1.1%) | ||
Heavy chain (NA = 4602) | IgA | 543 (25.4%) | 1036 (24.8%) | 479 (25.9%) | p = 0.13 |
IgG | 1560 (73%) | 3072 (73.6%) | 1339 (72.5%) | ||
Others | 35 (1.6%) | 67 (1.6%) | 30 (1.6%) | ||
Light chain (NA = 875) | Both | 3 (0.1%) | 20 (0.3%) | 2 (0.1%) | p < 0.001 |
Kappa | 1741 (65.6%) | 4167 (65.1%) | 1843 (65%) | ||
Lambda | 909 (34.3%) | 2212 (34.6%) | 991 (34.9%) | ||
Status after induction therapy (NA = 867) | CR | 220 (7.4%) | 759 (12.3%) | 354 (13%) | p < 0.001 |
VGPR | 20 (0.7%) | 1733 (28%) | 1105 (40.4%) | ||
PR | 2073 (69.8%) | 3033 (49%) | 1047 (38.3%) | ||
SD | 523 (17.6%) | 475 (7.7%) | 184 (6.7%) | ||
PD | 136 (4.6%) | 191 (3.1%) | 43 (1.6%) | ||
Status after 1st ASCT (NA = 2085) | CR | 518 (20.5%) | 1702 (29.7%) | 785 (32.3%) | p < 0.001 |
Never in CR | 2006 (79.5%) | 4022 (70.3%) | 1645 (67.7%) | ||
Renal Impairment (NA = 0) | yes | 541 (16.7%) | 1212 (18.3%) | 492 (16.8%) | p = 0.07 |
no | 2692 (83.3%) | 5398 (81.7%) | 2428 (83.2%) | ||
Regime (NA = 0) | single | 1110 (34.3%) | 3452 (52.2%) | 2019 (69.1%) | p < 0.001 |
tandem | 1533 (47.4%) | 1743 (26.4%) | 751 (25.7%) | ||
double | 475 (14.7%) | 1158 (17.5%) | 111 (3.8%) | ||
allo | 115 (3.6%) | 257 (3.9%) | 39 (1.3%) | ||
Cause of Death (NA = 8981) | No deaths during FU | 1092 (33.8%) | 4083 (61.8%) | 2567 (87.9%) | p < 0.001 |
HSCT related | 182 (5.6%) | 211 (3.1%) | 25 (0.9%) | ||
Relapse/PD | 1407 (43.5%) | 1604 (24.3%) | 206 (7.1%) | ||
Secondary malignancy | 48 (1.5%) | 84 (1.3%) | 15 (0.5%) | ||
other/unknown | 504 (15.6%) | 628 (9.6%) | 107 (3.7%) | ||
Cond. Dose (NA = 3694) | 100 mg/m2 | 86 (9.3%) | 278 (5.1%) | 75 (2.8%) | p < 0.001 |
140 mg/m2 | 114 (12.3%) | 1085 (19.8%) | 539 (20.3%) | ||
200 mg/m2 | 726 (78.4%) | 4130 (75.2%) | 2036 (76.8%) | ||
Age at first ASCT (NA = 0) | Median | 59.13 | 60.53 | 61.36 | p < 0.001 |
IQR | 12.02 | 11.81 | 10.98 | ||
Days to first ASCT (NA = 0) | Median | 197 | 180 | 191 | p < 0.001 |
IQR | 83 | 68 | 70 |
